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[57] ABSTRACT 
The present invention pertains to a method of protecting 
against neuron loss in a subject by administering a com 
pound that protects against neuron loss by acting through a 
vitamin D receptor. Some of these compounds may prevent 
or retard neuron loss by regulating intraneuronal and/or 
peripheral calcium and phosphate levels. Other compounds 
of the invention act through a vitamin D receptor to protect 
against neuron loss through mechanisms not involving cal 
cium or phosphate regulation. A preferred compound is a 
biologically active form of vitamin D, a precursor, 
metabolite, or analog of vitamin D. A preferred form of 
vitamin D is calcitriol. In another embodiment, the com 
pound is a compound that acts by modulating the biological 
activity of vitamin D, a precursor, metabolite, or analog of 
vitamin D. For example, the compound may modulate the 
biological activity of the vitamin D compound by regulating 
the amount of the vitamin D compound Which is available to 
protect against neuron loss or it may act by altering the 
ability of the vitamin D compound to protect against neuron 
loss. In an alternative embodiment, the compound is a 
compound that protects against neuron loss through a 
mechanism similar to that of the vitamin D compound but 
not involving a vitamin D receptor. The compound is 
administered to a subject in an amount and over a period of 
time effective to protect against neuron loss. 
42 Claims, No Drawings 
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METHOD OF PROTECTING AGAINST 
NEURON LOSS 
This application is a continuation of copending applica 
tion Ser. No. 08/594,379 ?led on Jan. 30, 1996 Which is a 
continuation of application Ser. No. 08/091,976 ?led Jul. 15, 
1993 noW abandoned. 
The Work described herein Was supported, in part, by 
grants from the United States government. 
BACKGROUND OF THE INVENTION 
Unlike many other cell types, neurons cannot be replaced 
in the adult brain. Thus, neuron loss in the adult brain has 
crippling and generally irreversible consequences Whether it 
is caused by age, disease, trauma, or combinations thereof. 
The cause of neuron loss during aging is unknoWn. Yet, 
there is increasing evidence suggesting that almost everyone 
Who lives long enough may succumb to age-related diseases, 
such as AlZheimer’s disease (AD), Parkinson’s disease (PD), 
and stroke, Which are generally associated With neuron loss 
in different regions of the brain. The incidence of many 
neurodegenerative diseases increases rapidly With aging. For 
example, the percent of the individuals beloW age sixty-?ve 
Who have AlZheimer’s disease is less than ?ve percent, but 
this incidence increases almost exponentially over age sixty 
?ve, and as many as forty-seven percent of individuals over 
eighty-?ve years of age may have some form of AD. 
KatZman, R. and Saitoh, T. (1991) FASEB J. 5:278—286; 
Evans, D. A. et al. (1989) JAMA 262:2551—2556. Moreover, 
the brains of essentially all individuals studied over age 
eighty contain at least some age- and/or disease-related 
neuron loss. Matsuyama, H. et al. (1966) Proceedings of the 
Fifth International Congress of Neuropathology (Excerpta 
Medica International Congress Series No. 100, eds. Luthy, F. 
et al.) 979—980. Thus, aging itself is the major risk factor for 
several types of neurodegenerative diseases, indicating that 
aging increases susceptibility to neuron loss. In fact, there is 
much evidence that aging, even in the absence of disease, is 
also associated With neuron loss and memory impairment. 
Crook, T. et al. (1986) Devel. Neuropsych. 2(4):261—276. 
Although the cause of neuron loss in aging and neurode 
generative diseases remains unknoWn, one model has been 
termed the “altered calcium homeostasis hypothesis”. This 
hypothesis is that dysregulated or elevated intracellular 
calcium levels is a “?nal common pathWay” for many 
neurodegenerative conditions and diseases that eventually 
leads to neuron death. It is based to a large extent on 
evidence of calcium dysregulation in age-related deteriora 
tion of the nervous system in animal models of aging. 
Khachaturian, Z. S. (1984) Handbook of Studies on Psy 
chiatry and Old Age (eds. Kay, D. and BuarroWs, G. D., 
Elsevier, Amsterdam) 7—30; Khachaturian, Z. S. (1989) 
Aging 1:17—34; Gibson, G. E. and Peterson, C. (1987) 
Neurobiol. Aging 8:329—344; Land?eld, P. W. (1987) Neu 
robiol Aging 8:346—347. It has also been shoWn that dys 
regulated or elevated intracellular calcium can lead to over 
activation of enZymes, such as calcium dependent proteases 
and endonucleases, that can be toxic to cells. Siesjo, B. K. 
(1981) J. Cereb. Blood FlowMetab. 1:155—185; Choi, D. W. 
(1987) J Neurosci. 7:369—379. 
While aging appears to affect calcium regulation in the 
brain, investigations of peripheral calcium regulation in 
relation to conditions and diseases, for example, AD, a 
disease marked by extensive neuron loss, notably in the 
hippocampus, generally have been inconsistent. Anumber of 
studies have found that neither parathyroid hormone, vita 
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min D, nor serum calcium differ systematically betWeen 
diseased patients and age-matched controls (Shore, D. et al. 
(1980) J. Gerontol. 35:656—662; Singh, S. (1988) Age 
Ageing 17:21—28; Ferrier, I. N. et al. (1990) Age Ageing 
19:368—375), While a feW have found that some aspects of 
calcium regulation are altered in diseased patients. Martyn, 
C. N. et al. (1989) Gerontology 35:153—157; Ferrier, I. N. et 
al. (1990) AgeAgeing 19:368—375; Ogihara, T. et al. (1990) 
Gerontology 36 (Supp. 1): 25—30. 
There have also been studies attempting to ?nd alterations 
in peripheral calcium regulating hormones With normal 
aging. Some of these studies found changes in calcium 
regulation and calcium regulating hormones such as vitamin 
D. OrWoll, E. S. and Meier, D. E. (1986) J. Clin. Endocrinol. 
Metab. 63:1262—1269. HoWever, all of these studies of 
peripheral calcium regulation in aging and even in AD have 
been correlational, and none has shoWn any causal link 
betWeen peripheral calcium regulating hormones and neuron 
loss. In fact, none of these studies has even suggested that 
vitamin D might affect brain calcium regulation or brain 
neuron loss. This is probably due to the generally held belief 
that peripheral hormones do not modulate brain calcium 
regulation. Thus, the concept of calcium regulation by 
vitamin D has not been related to the altered calcium 
homeostasis hypothesis of brain aging. 
Thus, the genetic or environmental cause(s) of brain aging 
or death of brain neurons, remain largely unde?ned. Clearly, 
Whatever the cause, it is the progressive and cumulative 
effect of neuron death over a long period of time that results 
in perceptible physiological changes. Progression of cogni 
tive symptoms due to AD have been found in longitudinal 
studies to be detectable at intervals of no less than one month 
to one year. Morris, J. C. et al. (1989) Neurology 
39:1159—1165 (Tables 3 and 6). Hippocampal neuron loss 
due to normal brain aging is even more gradual. Ball, M. J. 
(1977) Acta Neuropathol. (Berl.) 37:111—118; Coleman, P. 
D. and Flood, D. G. (1987) Neurobiol. ofAging 8:521—545. 
Thus, testing over a period of not less than one month, up to 
a period of perhaps several years, is necessary to shoW 
evidence of reduced neuron loss upon treatment of a subject 
With a drug that is purported to be useful in the treatment of 
age- or disease-related neurodegeneration. 
US. Pat. No. 4,897,388, issued in 1990 on an application 
?led in December, 1988 discloses a method of treating 
patients With AlZheimer’s disease through the administration 
of a safe and effective amount of a biologically active 
vitamin D3 or D2 material. One patient suffering from 
AlZheimer’s disease Was treated With calcitriol for a period 
of seven days. The patient’s condition, the symptoms of 
Which Were not de?ned, reportedly shoWed improvement. 
HoWever, the period over Which testing Was performed is 
completely insuf?cient, for the reasons stated above, to shoW 
evidence of reduced neuron loss. Additionally, the sample 
consisting of a single patient is not large enough from Which 
to determine any conclusions, even assuming that the 
improvement Was objectively determined. Finally, there is 
no explanation of the type of improvement observed but it 
is likely to be only the relief of AD symptoms caused by 
peripheral effects of the vitamin D material. 
Loss of neurons from the brain is thought to be a general 
characteristic of aging, affecting virtually all of the popula 
tion. Progressive neuron loss leads, in many circumstances, 
to the onset and progression of debilitating neurodegenera 
tive diseases, thus presenting a major healthcare burden for 
the population. For example, almost $90 billion Was spent in 
1991 alone on the treatment of patients With AlZheimer’s 
disease. (AlZheimer’s Association, Chicago, Ill.) This is just 
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one example of many diseases that may result from neuron 
loss. Any remedy Which could treat, or in the optimal case, 
prevent, occurrence of age-related neurological diseases by 
preventing neuron loss Would be an immense healthcare 
savings as Well as a great improvement in the health outlook 
for large number of the population. It is therefore imperative 
to develop therapies Which can halt or sloW the progression 
of neuron loss. Such therapies Would optimally Work over a 
long period of time as neuron loss occurs over a long period 
of time, and be safe in such time frames With efficacious 
dosages. For the foregoing reasons, there remains a critical 
need for a method of long term treatment that Will prevent 
or retard neuron loss in a subject. 
SUMMARY OF THE INVENTION 
The present invention provides a method of protecting a 
subject against neuron loss by administering to the subject a 
compound that protects against neuron loss by acting 
through the vitamin D receptor to prevent or retard neuron 
loss. The compound is administered in an amount and over 
a period of time effective to protect against neuron loss. In 
a preferred embodiment, the period of administration is over 
a long term, for example, greater than tWo Weeks and 
preferably one month or longer. 
Compounds of the present invention protect against neu 
ron loss by acting through a vitamin D receptor. Some of 
these compounds may prevent or retard neuron loss by 
regulating intraneuronal and/or peripheral calcium and 
phosphate levels. Other compounds of the invention act 
through a vitamin D receptor to protect against neuron loss 
through mechanisms not involving calcium or phosphate 
regulation. A preferred compound is a biologically active 
form of vitamin D, a precursor, metabolite, or analog of 
vitamin D (for ease of discussion beloW, the language 
“vitamin D compound” and “vitamin D, a precursor, 
metabolite, or analog of vitamin D” Will be used 
interchangeably) Which may or may not regulate calcium 
and/or phosphate levels. A preferred form of vitamin D is 
calcitriol. 
In another embodiment, the compound that is adminis 
tered to the subject is a compound that modulates the 
biological activity of the vitamin D compound. For example, 
the compound may modulate the biological activity of the 
vitamin D compound by regulating the amount of endog 
enous vitamin D compound Which is available to protect 
against neuron loss or it may act by altering the ability of the 
vitamin D compound to protect against neuron loss. In an 
alternative embodiment, the compound is a compound that 
regulates intraneuronal calcium levels through a mechanism 
similar to that of the vitamin D compounds but not involving 
a vitamin D receptor (for example, by a post receptor 
process that modulates intraneuronal calcium levels in a 
direction similar to that of vitamin D). 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. 1A, 1B, and 1C represent a schematic depiction of 
the method used to section the hippocampus in preparation 
for counting CA1 neurons in rats treated With calcitriol, 
calcitonin, or a control substance. The elongated hippocam 
pus (FIG. 1A) Was dissected free. Blocks of the hippocam 
pus Were processed by standard techniques for embedding in 
plastic. Thin sections (1 pm thick) Were cut from the block 
face (FIG. 1B) and ?eld CA1 neurons Were counted in six 
sections from each animal (FIG. 1C). 
FIGS. 2A and 2B are photographs illustrating density of 
the CA1 neurons in sections of hippocampus of aged rats 
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(26—27 months old). FIG. 2A is a photograph of a repre 
sentative hippocampal section from ?eld CA1 from an aged 
control rat. FIG. 2B is a photograph of a representative 
hippocampal section from ?eld CA1 of an aged rat after 8 
months of calcitriol injections. 
FIGS. 3A and 3B are bar graphs representing the average 
number of neurons in the CA1 region of the hippocampus in 
100 pm of the CA1 cell layer length for aged male rats 
injected over an 8 month period (FIG. 3A—age at initiation 
of treatment Was 19—20 months) or a 12 month period (FIG. 
3B—age at initiation of treatment Was 9—11 months) With 
either calcitriol, calcitonin, or a control substance. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention makes use of the discovery that a 
subject may be protected against neuron loss by adminis 
tering to the subject a compound Which acts through a 
vitamin D receptor to prevent and/or retard neuron loss. 
Because dysregulated calcium levels have been implicated 
in damage to neural tissues, one mechanism through Which 
some compounds of the present invention may protect 
against neuron loss is by restoring calcium homeostasis. 
Other compounds of the present invention act through the 
vitamin D receptor to protect against neuron loss Without 
regulating calcium levels. Typically, the compound is 
administered over a long term and in an amount suf?cient to 
protect against neuron loss. 
The term “protecting against” is intended to include 
prevention, retardation, and/or termination of deterioration, 
impairment, or death of a subject’s neurons. The compounds 
described herein provide protection against neuron loss. 
Neuron loss can be the result of any condition of a neuron 
in Which its normal function is compromised. Neuron dete 
rioration can be the result of any condition Which compro 
mises neuron function Which is likely to lead to neuron loss. 
Neuron function can be compromised by, for example, 
altered biochemistry, physiology, or anatomy of a neuron. 
Deterioration of a neuron may include membrane, dendritic, 
or synaptic changes Which are detrimental to normal neu 
ronal functioning. The cause of the neuron deterioration, 
impairment, and/or death may be unknoWn. Alternatively, it 
may be the result of age- and/or disease-related changes 
Which occur in the nervous system of a subject. 
When neuron loss is described herein as “age-related”, it 
is intended to include neuron loss resulting from knoWn and 
unknoWn bodily changes of a subject Which are associated 
With aging. When neuron loss is described herein as 
“disease-related”, it is intended to include neuron loss result 
ing from knoWn and unknoWn bodily changes of a subject 
Which are associated With disease. It should be understood, 
hoWever, that these terms are not mutually exclusive and 
that, in fact, many conditions that result in the loss of 
neurons are both age- and disease-related. 
Some of the more common age-related diseases associ 
ated With neuron loss and changes in neuronal morphology 
include, for example, AlZheimer’s disease, Pick’s disease, 
Parkinson’s disease, vascular disease, Huntington’s disease, 
and Age-Associated Memory Impairment. In AlZheimer’s 
patients, neuron loss is most notable in the hippocampus, 
frontal, parietal, and anterior temporal cortices, amygdala, 
and the olfactory system. The most prominently affected 
Zones of the hippocampus include the CA1 region, the 
subiculum, and the entorhinal cortex. Memory loss is con 
sidered the earliest and most representative cognitive change 
because the hippocampus is Well knoWn to play a crucial 
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role in memory. Pick’s disease is characterized by severe 
neuronal degeneration in the neocortex of the frontal and 
anterior temporal lobes Which is sometimes accompanied by 
death of neurons in the striatum. Parkinson’s disease can be 
identi?ed by the loss of neurons in the substantia nigra and 
the locus ceruleus. Huntington’s disease is characteriZed by 
degeneration of the intrastriatal and cortical cholinergic 
neurons and GABA-ergic neurons. Parkinson’s and Hun 
tington’s diseases are usually associated With movement 
disorders, but often shoW cognitive impairment (memory 
loss) as Well. 
Age-Associated Memory Impairment (AAMI) is another 
age-associated disorder that is characteriZed by memory loss 
in healthy, elderly individuals in the later decades of life. 
Crook, T. et al. (1986) Devel. Neuropsych. 2(4):261—276. 
Presently, the neural basis for AAMI has not been precisely 
de?ned. HoWever, neuron death With aging has been 
reported to occur in many species in brain regions impli 
cated in memory, including cortex, hippocampus, amygdala, 
basal ganglia, cholinergic basal forebrain, locus ceruleus, 
raphe nuclei, and cerebellum. Crook, T. et al. (1986) Devel. 
Neuropsych. 2(4):261—276. 
Subjects Who can be treated by the method of this 
invention include living organisms, e.g. mammals, suscep 
tible to age- and/or disease-related neuron loss. Examples of 
subjects include humans, dogs, cats, rats, and mice. Lower 
mammal models using, for example, rats or mice can be used 
to predict modes of general brain aging and associated 
neuron loss in higher mammals, such as humans. 
Aging rodent brains do not develop senile plaques and 
neuro?brillary tangles. Most recent studies suggest, 
hoWever, that loss or shrinkage of neurons, dendrites, and/or 
synapses is more closely correlated With either dementia or 
aging than are plaques and tangles. Terry, R. D. et al. (1987) 
Ann. Neurol. 21:530—539; Terry, R. D. et al. (1990) J. 
Neuropathol. Exp. Neurol. 491335; Buell, S. J. and Coleman, 
P. D. (1981) Brain Res. 214:23—41; Scheff, S. W. et al. 
(1990) Neurobiol. Aging 11:29—37. Aging rats exhibit neu 
ronal cell loss in the pyramidal cells of the hippocampus, 
especially in ?eld CA1, (Land?eld, P. W. et al. (1981) 
Science 214:581—584; Land?eld, P. W. (1987) Prog. Brain 
Res. 72:279—300; Kerr, D. S. et al. (1991) J. Neurosci. 
11:1316—1324) as Well as cell loss or dendritic/synaptic 
changes in some other brain regions. Coleman, P. D. and 
Flood, D. G. (1987) Neurobiol. Aging 8:521—545; 
Geinisman, Y. et al. (1986) Brain Res. 398:266—275. 
Moreover, aging rodents shoW extensive hippocampal astro 
cyte hypertrophy (Land?eld, P. W. et al. (1977) J. Gerontol. 
32:3—12; Land?eld, P. W. et al. (1978) Science 
202:1098—1102; Geinisman, Y. et al. (1978) Am. J. Anat. 
153:537—544) just as do aging humans. WisnieWski, H. M. 
and Terry, R. D. (1973) Progress in Brain Research (ed. 
Ford, D. M. Elsevier, Amsterdam) 40:167—186; Hansen, L. 
A. et al. (1987) Neurobiol. Aging 8:1—6. In addition, loss of 
neurons in ?eld CA1 of the hippocampus is a consistent 
correlate of aging across species, and is also prominent in 
human neurodegenerative diseases, such as AD. For these 
reasons, the study of neuron loss in aging rats, for example, 
is predictive of general mechanisms of brain aging and 
associated neuron loss in humans. 
Because of the great dif?culty associated With measuring 
brain neuron loss in living humans or even in autopsy 
material, Which is highly variable and often shoWs massive 
changes due to the postmortem interval prior to ?xation, 
many neuroprotective inventions have been based on in vitro 
tissue culture systems of neurons from embryonic rodent 
pups (See eg US. Pat. No. 5,179,109-fetal rat tissue 
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culture), or other mammalian (See eg US. Pat. No. 5,089, 
517-fetal mouse tissue culture) or non-mammalian animal 
models. These inventions have been for protection of periph 
eral as Well as central nervous system neurons in animal or 
tissue culture models of ischemia, stroke, trauma, nerve 
crush, AD, and PD, etc. Neuron deterioration in these model 
systems is often proved by experimental trauma or inter 
vention (e.g. application of toxins, nerve crush, interruption 
of oxygen supply, etc.). For example, in order to demonstrate 
that certain N-methyl-D-aspartate (NMDA), an excitatory 
amino acid neurotransmitter receptor, antagonists Were use 
ful as anticonvulsants and neuroprotectants, the inventors in 
US. Pat. No. 4,957,909 employed a model Wherein SWiss 
albino mice and rat hippocampal neurons Were subjected to 
overstimulation of excitatory amino acid receptors subse 
quent to treatment With the NMDA antagonists. A similar 
study Was performed Wherein the utility of certain NMDA 
antagonists as agents that prevent neurodegeneration Was 
demonstrated by treating mice With NMDA subsequent to 
treatment With the NMDA antagonists. US. Pat. No. 5,168, 
103. Another experimental model Wherein the inventors, in 
order to demonstrate the ability of indolactam V compounds 
to prevent destruction of neocortical neurons, exposed in 
vitro cultures of fetal mouse neurons and glial cells to 
various glutamate agonists, such as kainate, NMDA, and 
ot-amino-3-hydroxy-5-methyl-4-isoxaZolepronate (AMPA). 
US. Pat. No. 5,089,517. See also US. Pat. No. 5,170,109 
(treatment of rat cortical/hippocampal neuron cultures With 
glutamate prior to treatment With neuroprotective 
compound); US. Pat. Nos. 5,163,196 and 5,196,421 
(neuroprotective excitatory amino acid receptor antagonists 
inhibit glycine, kainate, AMPA receptor binding in rats). 
HoWever, the present animal model represents an 
improvement in the model for age-associated neuroprotec 
tion because it relates to an intact animal, Which is generally 
preferred over tissue culture models, and employs a strain of 
rat that Was developed by the National Institute on Aging as 
a premier model of mammalian aging. The particular rat 
strain (BroWn NorWay/Fischer 344 F1 cross rats) Was 
selected as such a model due to its normal pattern of aging, 
With feW indications of abnormal pathology. This strain also 
loses neurons in ?eld CA1 of the hippocampus With aging 
and exhibits memory loss. This system represents one of the 
most natural animal models of neuron degeneration and/or 
deterioration because it re?ects a gradual loss of neurons. 
Furthermore, the neuron loss is not provoked by experimen 
tal intervention or abnormal pathology. Its brain aging 
pattern is also highly analogous to human and other mam 
malian species’ brain aging patterns. 
The compound is administered through a route Which 
alloWs the compound to perform its intended function of 
protecting against neuron loss in a subject. Examples of 
routes of administration Which may be used in this method 
include parenteral (subcutaneous, intravenous, 
intramuscular, intraarterial, intraperitoneal, intrathecal, 
intracardiac, and intrasternal), enteral administration (i.e. 
administration via the digestive tract), mucosal 
administration, and percutaneous administration. Depending 
on the route of administration, the compound may be coated 
With or in a material to protect it from the natural conditions 
Which may detrimentally affect its ability to perform its 
intended function. A particularly convenient method of 
administering a compound of the present invention, for 
example a vitamin D compound, is percutaneous adminis 
tration. 
The administration of the compound is performed in 
accordance With the invention, at dosages and for periods of 
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time effective to protect against the loss of neurons in a 
subject. Dosage regimes may be adjusted for purposes of 
improving the therapeutic response to the compound. For 
example, several divided doses may be administered daily or 
the dose may be proportionally reduced as indicated by the 
exigencies of the therapeutic situation. 
Compounds of the present invention protect against neu 
ron loss by acting through a vitamin D receptor. Vitamin D 
receptors are Well knoWn to exist in the periphery but have 
also been found in the brain, particularly in the hippocampus 
and neocortex. Some of these compounds may prevent or 
retard neuron loss by regulating intraneuronal and/or periph 
eral calcium and phosphate levels. Other compounds of the 
invention act through a vitamin D receptor to protect against 
neuron loss through mechanisms not involving calcium or 
phosphate regulation. The compounds that act by regulating 
calcium and/or phosphate levels modulate calcium and/or 
phosphate homeostasis of either peripheral or intraneuronal 
calcium and/or phosphate or restore dysregulated calcium to 
normal levels, thereby providing protection against neuron 
loss. 
One Way a compound can protect against neuron loss by 
acting through the vitamin D receptor is by modulating the 
biological activity of a vitamin D compound. This can be 
done by modulating the amount of the vitamin D compound 
that is available to protect against neuron loss. Generally, the 
compound Will increase the amount of vitamin D compound 
that is available to protect against neuron loss by increasing 
the synthesis or expression of the vitamin D compound. For 
example, the biphosphonate YM175 (methylene-1,1 
biphosphonate) has been found to stimulate renal production 
of 1,25 dihydroxy-vitamin D by stimulating renal 
1-hydroxylase activity in rats. Nagao, Y. et al. (November 
1991) Biochem. Biophys. Res. Comm. 180(3): 1172—1178. 
Renal 1-hydroxylase is an enZyme that hydroxylates 25 
dihydroxy vitamin D to yield 1,25 dihydroxy vitamin D, or 
calcitriol Which is believed to be one of the most active 
metabolites of vitamin D. Another biphosphonate, HPeBP 
(1-hydroxypentane-1,1-biphosphonate), has been shoWn to 
induce stimulation of 1,25 dihydroxy-vitamin D. Bonjour, 
J .-P. et al. (1988) Am. J. Physiol. 254:E260—E264. Vitamin 
D receptor agonists also contribute to the regulation of the 
amount of the vitamin D compound that is available to 
protect against neuron loss. 
Another Way in Which a compound of the present inven 
tion can protect against neuron loss by acting through a 
vitamin D receptor is by altering the ability of the vitamin D 
compound to protect against neuron loss. Such compounds 
include binding proteins, such as vitamin D-binding protein. 
These proteins may act by increasing the stability of the 
vitamin D compound. There are still other neuroprotective 
compounds, such as other steroids or related compounds, 
Which may not act through the vitamin D receptor but may 
regulate, directly or indirectly, calcium and/or phosphate 
levels in a manner similar to that of vitamin D (for example, 
by a post receptor process that modulates intraneuronal 
calcium levels in a direction similar to that of vitamin D). 
Such compounds include, for example, glucocorticoid 
receptor antagonists such as mifepristone, mifepristone 
derivatives (See eg U.S. Pat. No. 4,386,085), and dehy 
droepiandrosterone (DHEA). 
In a preferred embodiment, the compound is a biologi 
cally active form of vitamin D, or a precursor, metabolite, or 
analog of vitamin D. Vitamin D is generally classi?ed as a 
steroid hormone because of its hormonelike relationship 
With calcium and phosphate metabolism, its pathWay of 
molecular modi?cation to yield active metabolites, and its 
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mechanism of action Which is similar to those of other 
steroid hormones. The language “vitamin D, precursor, 
metabolite, or analog of vitamin D” is intended to include 
vitamin D or an analog thereof, in any stage of its metabo 
lism. This language is also intended to include mixtures of 
different metabolic forms of vitamin D or a vitamin D 
analog. The vitamin D compounds may preserve or restore 
calcium homeostasis by interfering With mechanisms Which 
result in neurotoxic levels of calcium and/or phosphate. 
Alternatively, the vitamin D compounds may protect against 
neuron loss through mechanisms not involving calcium 
regulation. Generally, there are tWo sources of vitamin D in 
most mammals. One source is vitamin D produced in the 
skin by ultraviolet irradiation (D3 or cholecalciferol). 
Another source is vitamin D ingested in the diet (D2 or 
ergocalciferol). D2 and D3 have identical biological actions. 
Vitamin D2 and D3 compounds include, for example, 
dihydrotachysterol2, dihydrotachysterol3, 5,6-trans 
cholecalciferol, 25-hydroxy-5,6-trans cholecalciferol, 
1ot-hydroxy ergocalciferol (1ot-OHD2), 25-hydroxy ergocal 
ciferol (25-OHD2), 10., 25-dihydroxy ergocalciferol (10., 
25-(OH)2D2), 10., 25-dihydroxy cholecalciferol (10., 25 
(OH)2D3), 10., 24, 25-trihydroxy cholecalciferol (10., 24, 
25-(OH)3D3), 24,25-dihydroxy cholecalciferol (24,25-(OH) 
2D3), 10., 24-dihydroxy-25-?uoro cholecalciferol (10., 24 
(OH)2 25 -FD3), 25 -hydroxy cholecalciferol (25-OHD3), and 
1ot-hydroxy cholecalciferol (1ot-OHD3). 
Vitamin D2 and D3 precursors and metabolites are also 
biologically active. Vitamin D2 or D3 precursors and 
metabolites include, for example, 1ot25-dihydroxy-B 
7-dehydrocholesterol (10., 25-(OH)2 proD3), 10., 24,25 
trihydroxy-7-dehydrocholesterol (10., 24,25-(OH)3 proD3), 
24,25-dihydroxy-7-dehydrocholesterol (24,25-(OH)2 
proD3), 10t-hydroxy-7-dehydrocholesterol (lot-OH proD3), 
10., 24-dihydroxy-25-?uoro-7-dehydrocholesterol (10., 24 
(OH)2-25F proD3), 25,26-dihydroxy-7-dehydrocholesterol 
(25 ,26-(OH)2 proD3), 25-hydroxy-7-dehydrocholesterol 
(25-OH proD3), 25-hydroxy ergosterol (25-OH proD2), 10., 
25-dihydroxy ergosterol (10., 25-(OH)2 proD2), 10., 
25-dihydroxy precholecalciferol (10., 25-(OH)2 preD3), 10., 
24,25-trihydroxy precholecalciferol (10., 24, 25-(OH)3 
preD3), 24,25-dihydroxy precholecalciferol (24,25-(OH)2 
preD3), 1ot-hydroxy precholecalciferol (lot-OH preD3), 10., 
24-dihydroxy-25-?uoro-precholecalciferol (10., 24-(OH)2 
25F preD3), 25-hydroxy-precholecalciferol (25-OH preD3), 
1ot-hydroxy-previtamin D2 (lot-OH preD2), 25-hydroxy 
previtamin D2 (25-OH preD2), and 10., 25-dihydroxy 
previtamin D2 (10., 25-(OH)2 preD2). 
A vitamin D3 metabolite Which is particularly useful in 
the method of the present invention is 1,25 dihydroxychole 
calciferol (1,25 (OH)2-D3 or calcitriol). Calcitriol is believed 
to be one of the most active forms of vitamin D3. It is 
presently commercially available in capsule form 
(ROCALTROL®, Roche Laboratories) or in injection form 
(CALCIJEX®, Abbott Laboratories, Inc.). 
The term “biologically active” is intended to include an 
activity for the vitamin D, precursor, metabolite, or analog 
of vitamin D, Which alloWs it to perform its intended 
function. It is knoWn in the art that vitamin D compounds 
display varying degrees of activity and it is contemplated 
that any of the biologically active forms of vitamin D can be 
used in the method of this invention. 
The compound is administered over a period of time 
effective to protect against neuron loss in a subject. 
Typically, the treatment period Will be over a long term. The 
phrase “long term,” as used herein is a time period of such 
a duration that a subject treated With the compound, When 
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compared With a subject not so treated, is protected against 
neuron loss. Generally, changes in neuron number are not 
apparent until at least approximately tWo Weeks into the 
treatment. Thus, “long term” administration of the com 
pound refers to a period of administration of greater than tWo 
Weeks, and usually about one month, or longer. Preferably, 
the administration is over a period of time from about six 
months to one year or longer. 
An amount of the compound Which is effective to protect 
against neuron loss in a subject is the amount of compound 
sufficient to prevent, retard, and/or terminate deterioration, 
impairment, and/or death of a neuron. The dose of the 
compound suf?cient to protect against neuron loss is depen 
dent both on the speci?c activity of the compound and its 
concentration. Choice of an appropriate dose can be deter 
mined on an individual basis and Will be based, at least in 
part, on consideration of the severity of the symptoms to be 
treated and the activity of the speci?c compound used. 
Further, the effective amounts of the compound may vary 
according to the age, sex, and Weight of the subject being 
treated. Thus, an effective amount of the compound can be 
determined by one of ordinary skill in the art employing 
such factors as described above using no more than routine 
experimentation. 
The invention is further illustrated by the folloWing 
non-limiting examples. The contents of all references and 
issued patents cited throughout this application are expressly 
incorporated herein by reference. 
EXAMPLES 
Animals 
The rats used in this experiment Were male BroWn Nor 
Way x Fischer 344 F1 cross hybrid rats Which Were obtained 
from the National Center for Toxicology Research 
(Jefferson, Ark.). These F1 cross hybrid rats Were main 
tained in a largely germ-free (speci?c pathogen free) envi 
ronment and have a mean longevity When maintained in 
such a controlled environment of about 29—30 months of 
age. The animals continued to be maintained, throughout the 
injection period, in laminar air ?oW ?lter barriers in animal 
facilities and fed, ad libitum, a diet of rodent choW and 
Water. Animals Were Weighed Weekly to monitor any effect 
of the drugs on their body Weight and health. Food and Water 
study Was done during the ?rst months to monitor effect of 
drugs on their food consumption. All animals that displayed 
any physical health problems Were necropsied and blood 
Was taken for analysis. During necropsy, organ condition 
and pathologies Were noted. 
Animals Were kept on six foot animal racks and each drug 
group had the same number of animals in every position at 
the start of the study. Positioning the rats in order to equaliZe 
the amount of light to Which they Were exposed Was impor 
tant because serum vitamin D levels can be in?uenced by the 
amount of light that the rats received. 
Three groups, each consisting of betWeen eight and thir 
teen rats, Were carefully selected and matched for age and 
body Weight at the start of each study. In the ?rst study, rats 
betWeen 18 and 19 months of age Were subjected to drug 
injections for a period of 8 months. At the end of the 
injection period, the rats Were betWeen 26 and 27 months 
old. In the second study, rats betWeen 9 to 11 months of age 
Were subjected to drug injections for a period of 12 months. 
At the end of the injection period, the rats Were betWeen 21 
and 23 months old. 
Drugs 
Calcitriol (CALCIJEX®, in 2 mg/ml vials, Was obtained 
from Abbott Laboratories, Inc (Abbott Park, 111.). A test 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
10 
group of rats received subcutaneous injections of calcitriol 
daily at the rate of 20 ng/rat/day for ?ve consecutive days 
per Week. For the 18—19 month old rats, the injections 
continued for a period of 8 months. For the 9—11 month old 
rats, the injections continued for a period of 12 months. 
Salmon calcitonin Was obtained from either Bachem 
(Torrance, Calif.) or Calbiochem (San Diego, Calif.) in 1 mg 
vials. The peptide Was kept in aliquot form in light-free 
conditions in a —40° C. freeZer and diluted daily for injec 
tion. The diluant consisted of a ?ltered and autoclaved 
solution of the folloWing components: 20 mg polysorbate, 
45 mg NaCl, 300 mg ascorbic acid, 228 mg dibasic phos 
phate buffer, 54 mg monophosphate buffer, and 30 mg 
EDTA. This diluant Was used in order to match the vehicle 
in Which calcitriol is commercially available. A second 
group of rats received subcutaneous injections at a dose of 
2 IU/rat/day (?ve days/Week) of calcitonin. A control group 
of rats received subcutaneous injections of a control solution 
consisting of the same ingredients in the same amounts as 
the CALCIJEX® solutions, minus the calcitriol or 
calcitonin, at the same rate. For the 18—19 month old rats, the 
injections of calcitonin and the control substance continued 
for a period of 8 months. For the 9—11 month old rats, the 
injections of calcitonin and the control substance continued 
for a period of 12 months. 
In order to assure that the drugs Were biologically active 
and to determine that there Were no toxic side effects 
produced by the drugs, the animals that Were used for 
hippocampal cell density measurements in the 8 month 
injection study also had blood analysis tests done. (Table I) 
Blood Was collected after the injection of sodium pentobar 
bital and just prior to intracardial perfusion, using a 
vacutainer, for blood collection. 
Tissue Preparation 
Upon completion of both the 8 and 12 month injection 
periods, the animals in the calcitriol-treated, calcitonin 
treated and control-treated groups Were injected With a lethal 
dose of sodium pentobarbital. The animals Were alloWed to 
reach a deep level of anesthesia before the perfusion Was 
initiated. Blood Was taken from the left ventricle just prior 
to the perfusion by the ?xative. Table I illustrates the effects 
of calcitriol and calcitonin on the levels of calcium in the 
blood of the rats Which Were 18—19 months old at the 
initiation of the injections after 8 months of injections. As 
Was expected, calcitriol treatment resulted in a signi?cantly 
increased level of blood calcium and phosphorous over that 
in the blood of controls. Calcitonin treatment resulted in 
blood calcium levels slightly but not signi?cantly above that 
found in the blood of controls. Data shoWn are 
means:S.E.M. 
TABLE I 
BLOOD SUMMARY FOR BROWN NORWAY X F344 
RATS AFTER 8 MONTHS OF INJECTION 
Control Calcitriol Calcitonin 
Body Weight 574.4 1 529.2 + 559.7 1 
(p = 0.2171) 26.9 13.11 14.93 
Sodium 144.6 1 146.2 + 146.4 1 
(p = 0.2831) 1.32 0.48 0.62 
Potassium 5.15 r 5.46 r 5.13 r 
(p = 0.5890) .328 0 272 0.195 
Chloride 100.73 1 98.42 1 93.60 1 
(p = 0.5403) 1.01 0.489 6.966 
C02 29.00 1 29.75 1 29.66 1 
(p = 0.7400) 0.735 0 657 0.744 
Urea 19.91 1 15.92 1 18.86 1 
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TABLE I-continued 
BLOOD SUMMARY FOR BROWN NORWAY X F344 
RATS AFTER 8 MONTHS OF INJECTION 
Control Calcitriol Calcitonin 
(p = 0.3365) 1.237 0.983 2.595 
Glucose 168.82 1 183.75 1 166.20 1 
(p = 0.4467) 14.100 8.776 9.643 
Calcium 10.282 1 11.10** 1 10.314 1 
(p = 0.0003)M .13772 .13236 .16127 
Phosphorus 4.336 r 4.842** r 4.100 r 
(p = 0.0065)M .15954 0.1727 0.1607 
Creatinine 0.555 1 0.4667 1 0.5933 1 
(p = 0.0963) 0.0389 0.02346 0.0529 
Uric Acid 0.6545 1 0.9833 1 0.9600 1 
(p = 0.5229) 0.2471 0.2219 0.2077 
Cholesterol 101.727 1 90.250 1 89.733 1 
(p = 0.1464) 5.0737 4.814 4.516 
Protein 6.100 1 6.2250 1 6.0467 1 
(p = 0.6626) 0.1697 0.0814 0.1653 
Albumin 2.918 1 3.0500 1 2.8733 1 
(p = 0.5839) 0.1902 0.302 0.127 
Total Bilirubin 0.200 r 0.208 r 0.213 r 
(p = 0.9095) 0.245 0.0239 0.0199 
Alkaline 127.636 1 99.00 1 87.333 1 
(p = 0.1386) 27.47 5.5402 6.9324 
Glut. Oxaloacetic Transaminase 116.091 1 103.167 1 110.987 1 
(p = 0.8486) 15.653 17.779 14.398 
Lactate Dehydrogenase 277.818 1 284.00 1 377.600 1 
(p = 0.5820) 74.7116 70.393 87.925 
Iron 171.546 1 195.083 1 187.533 1 
(p = 0.766) 26.899 13.266 24.778 
Magnesium 1.813 r 1.725 1 1.7091 1 
(p = 0.4625) 0.0426 0.0670 0.0574 
Corticosterone 302.143 1 280.273 1 283.364 1 
(p = NS) 55.019 32.364 48.163 
Subsequently, the animals Were perfused With a 2% 
glutaraldehyde-2% paraformaldehyde ?xative solution at 4° 
C. for 30 minutes. After perfusion Was completed, the brain 
of each animal Was dissected and placed in the 2% 
glutaraldehyde-2% paraformaldehyde ?xative overnight at 
4° C. 
The frontal lobes and cerebellum Were dissected aWay and 
the remaining hippocampus and cortex Were cut in 250 pm 
thick sections starting at the most anterior portion of the 
hippocampus. The resulting sections Were collected serially 
into sodium cacodylate buffer. The section that Was 2250 pm 
posterior in the ?rst experiment and 1750 pm posterior in the 
second experiment Was consistently used for comparison 
among the three groups of animals. 
Light Microscopy 
The 250 pm-thick sections Were processed as indicated by 
the standard embedding for electron microscopy or for 
“semithin” sections used in light microscopy. Peters, A. and 
Palay, S. L., The Fine Structure of the Nervous System 
(Harper & RoW, NeW York 1970); Land?eld, P. W. et al. 
(1981) Neurobiol. Aging 2:265—275. Blocks Were in?ltrated 
With Epon 812 from Ted Pella (Redding, Calif.). 
After embedding, 1 pm-thick semithin sections containing 
at least several hundred pm of the CA1 neuron layer Were 
cut from the face of the 250 pm-thick section. (See FIGS. 
1A, 1B, and 1C) The ?rst ?ve Wells of a glass slide Were 
?lled With adjacent semithin sections and then the next 50 
pm of the section block Was discarded. Then ?ve additional 
semithin sections Were cut serially into another ?ve Wells. 
Discarding the intervening 50 pm alloWed for sampling of a 
larger region of the hippocampus. Semithin sections Were 
then stained With Toluidine Blue and coverslipped for analy 
sis. 
For each animal, three pairs of the adjacent sections Were 
photographed. The cells that had the beginning “top” of one 
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neuron starting in one photograph but not in the other 
adjacent section of the pair Were counted for each animal. 
This is a neW stereological method that provides a reliable 
index of number of neurons in a section, Which is unbiased 
by shape or size of the neurons. Pakkenberg, B. and 
Gundersen, H. J. G. (1989) APMIS 97:677—681; West, M. 
and Gunderson, H. (1990) J. Comp. Neurol. 296:1—22. The 
length of the cell layer in each section Was measured using 
a calibrated imaging system (Sigma Scan) and the average 
number of CA1 neurons/ 100 pm of the CA1 cell layer length 
Was obtained. FIGS. 2A and 2B shoW photographs illustrat 
ing CA1 neurons in the hippocampus of rats between the 
ages of 26—27 months after they have been injected over an 
8 month period With a control substance (FIG. 2A) or 
calcitriol (FIG. 2B). After the injection period, the hippoc 
ampal tissue Was embedded, sectioned (1 pm), and stained 
With Toluidine Blue. After calcitriol treatment (FIG. 2B), a 
greater density of neurons appears in the hippocampal 
section. After treatment With the control substance (FIG. 
2A), there are gaps and empty regions Where the hippoc 
ampal neurons have died. 
The average number of CA1 neurons/ 100 pm of the CA1 
cell layer length for the calcitriol, calcitonin, and control 
groups for both experiments is shoWn in FIGS. 3A and 3B. 
FIGS. 3A and 3B shoW bar graphs illustrating the number of 
CA1 neurons/100 pm of the CA1 cell layer length in 
hippocampal sections of calcitriol-treated, calcitonin 
treated, and control-treated rats after 8 and 12 months of 
injections. Rats of tWo different age groups Were used, the 
group treated for 8 months being substantially older (18—19 
months) than the group treated for one year (9—11 months) 
at the start of the study. Neuron loss in the rats that Were 
treated With calcitriol Was prevented, inhibited, and/or 
retarded as compared to the rats treated With the control 
injection. The average number of CA1 neurons/100 pm of 
the CA1 cell layer length in the hippocampal sections of the 
12 month (FIG. 3A) calcitriol-treated group Was about 1.65, 
While the average number of CA1 neurons/100 pm in the 
control group Was about 1.4. The calcitonin-treated group of 
rats had the loWest average number of CA1 neurons/100 pm 
With about 1.3 CA1 neurons/100 pm. 
The average number of CA1 neurons/ 100 pm of the CA1 
cell layer length in the hippocampal sections of the 8 month 
(FIG. 3B) calcitriol-treated group Was about 1.4, While the 
average number of CA1 neurons/100 pm in the control 
group Was about 1.2. The calcitonin-treated group of rats had 
the loWest average number of CA1 neurons/100 pm With 
about 1.1 CA1 neurons/100 pm. These results clearly dem 
onstrate that long term treatment With calcitriol prevents 
and/or retards neuron loss in aging rats. 
Equivalents 
Those skilled in the art Will recognize, or be able to 
ascertain using no more than routine experimentation, many 
equivalents to the speci?c embodiments of the invention 
described herein. Such equivalents are intended to be 
encompassed by the folloWing claims. 
I claim: 
1. Amethod for protecting against neuron loss in a subject 
affected With neuron loss resulting from a neurodegenerative 
condition, comprising: 
(a) providing a compound Which protects against neuron 
loss by acting through a vitamin D receptor; and 
(b) administering the compound to the subject in an 
effective amount and over an effective period of time, 
so as to provide protection against neuron loss. 
2. The method of claim 1 Wherein the compound is 
administered over a long term. 
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3. The method of claim 2 wherein the period of admin 
istration is about siX months or longer. 
4. The method of claim 1 Wherein the compound regulates 
intraneuronal calcium levels. 
5. The method of claim 1 Wherein the compound regulates 
peripheral calcium levels. 
6. The method of claim 2, Wherein the period of admin 
istration is about 1 month or longer. 
7. The method of claim 1 Wherein the compound regulates 
peripheral phosphate levels. 
8. The method of claim 1 Wherein the compound regulates 
intraneuronal phosphate levels. 
9. The method of claim 1 Wherein the neuron loss is 
age-related. 
10. The method of claim 1 Wherein the neuron loss is 
disease-related. 
11. The method of claim 1 Wherein the neuron loss is age 
and disease-related. 
12. The method of claim 1, Wherein the neurodegenera 
tive condition is selected from the group consisting of 
AlZheimer’s disease, Pick’s disease, Parkinson’s disease, 
Vascular Disease, Stroke, Age Associated Memory 
Impairment, and Huntington’s disease. 
13. The method of claim 1 Wherein the subject is a 
mammal. 
14. The method of claim 13 Wherein the mammal is a 
human. 
15. The method of claim 1 Wherein the compound is 
parenterally administered to the subject. 
16. The method of claim 1 Wherein the compound is 
enterally administered to the subject. 
17. The method of claim 1 Wherein the compound is a 
biologically active form of vitamin D, a precursor, 
metabolite, or analog of vitamin D. 
18. The method of claim 17 Wherein the vitamin D, 
precursor, metabolite, or analog of vitamin D, is selected 
from the group consisting of dihydrotachysterol2, 
dihydrotachysterol3, 5,6-trans-cholecalciferol, 25-hydroXy 
5,6-trans cholecalciferol, lot-hydroxy ergocalciferol, 
25-hydroXy ergocalciferol, 10., 25-dihydroXy ergocalciferol, 
10., 25-dihydroXy cholecalciferol, 10., 24, 25-trihydroXy 
cholecalciferol, 24,25-dihydroXy cholecalciferol, 10., 
24-dihydroXy-25-?uoro cholecalciferol, 25-hydroXy 
cholecalciferol, lot-hydroxy cholecalciferol, 10., 
25-dihydroXy-B 7-dehydrocholesterol, 10., 24,25 
trihydroXy-7-dehydrocholesterol, 24,25-dihydroXy-7 
dehydrocholesterol, 1ot-hydroXy-7-dehydrocholesterol, 10., 
24-dihydroXy-25-?uoro-7-dehydrocholesterol, 25,26 
dihydroXy-7-dehydrocholesterol, 25-hydroXy-7 
dehydrocholesterol, 25-hydroXy ergosterol, 10., 
25-dihydroXy ergosterol, 10., 25-dihydroXy 
precholecalciferol, 10., 24,25-trihydroXy precholecalciferol, 
24,25-dihydroXy precholecalciferol, lot-hydroxy 
precholecalciferol, 10., 24-dihydroXy-25-?uoro 
precholecalciferol, 25-hydroXy-precholecalciferol, 
1ot-hydroXy-previtamin D2, 25-hydroXy-previtamin D2, and 
10., 25-dihydroXy-previtamin D2. 
19. The method of claim 18 Wherein the vitamin D 
metabolite is calcitriol. 
20. The method of claim 1 Wherein the compound modu 
lates the biological activity of vitamin D, a precursor, 
metabolite, or analog of vitamin D, in a manner effective to 
protect against neuron loss. 
21. The method of claim 20 Wherein the compound 
regulates the amount of the vitamin D, precursor, metabolite, 
or analog of vitamin D, Which is available to protect against 
neuron loss. 
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22. The method of claim 20 Wherein the compound alters 
the ability of vitamin D, or a precursor or metabolite of 
vitamin D, to protect against neuron loss. 
23. A method according to claim 1, Wherein the subject is 
other than a patient suffering from AlZheimer’s disease. 
24. A method according to claim 1, Wherein the neuro 
degenerative condition is AlZheimer’s disease. 
25. Amethod of protecting against neuron loss in a subject 
affected With neuron loss resulting from a neurodegenerative 
condition, comprising: 
(a) providing a biologically active form of vitamin D, a 
precursor, metabolite or analog of vitamin D; and 
(b) administering the biologically active form of vitamin 
D, a precursor, metabolite, or analog of vitamin D to the 
subject in an amount and over a period of time, 
determined to be effective to provide protection against 
neuron loss. 
26. The method of claim 25 Wherein the subject is a 
mammal. 
27. The method of claim 26 Wherein the mammal is a 
human. 
28. The method of claim 25 Wherein the vitamin D 
metabolite is calcitriol. 
29. The method of claim 25, Wherein the period of 
administration is about one month or longer. 
30. The method of claim 29, Wherein the period of 
administration is about siX months or longer. 
31. The method of claim 25, Wherein the compound is 
administered over a long term. 
32. The method of claim 25, Wherein the neurodegenera 
tive condition is selected from the group consisting of 
AlZheimer’s disease, Pick’s disease, Parkinson’s disease, 
Vascular Disease, Age Associated Memory Impairment, 
Stroke, Huntington’s disease. 
33. A method according to claim 25, Wherein the neuro 
degenerative condition is AlZheimer’s disease. 
34. A method according to claim 33, Wherein the neuro 
degenerative condition is AlZheimer’s disease. 
35. A method of protecting against neuron loss in a 
subject, comprising: 
(a) providing a biologically active form of a steroid, or 
metabolite or analog of a steroid Which protects against 
neuron loss through a mechanism similar to that of 
vitamin D but not acting through the vitamin D recep 
tor; and 
(b) administering the biologically active form to the 
subject in an amount and over a period of time, 
determined to be effective Without reference to provid 
ing acute alleviation of symptoms in the subject, so as 
to provide protection against neuron loss, such protec 
tion being independent of any acute alleviation of such 
symptoms. 
36. A method of protecting against neuron loss in a 
subject, comprising: 
(a) providing a compound other than vitamin D2 or 
vitamin D3, their corresponding previtamins and 
provitamins, metabolites and analogues, capable of 
acting through a vitamin D receptor; and 
(b) administering the compound in an amount and over a 
period of time, determined to be effective so as to 
provide protection against neuron loss. 
37. Amethod of protecting against neuron loss in a subject 
at increased risk of neurological impairment by reason of at 
least one of aging and disease, other than AlZheimer’s 
disease, comprising: 
(a) providing a biologically active form of vitamin D, a 
precursor, metabolite or analog of vitamin D; and 
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(b) administering the biologically active form of vitamin 
D, a precursor, metabolite, or analog of vitamin D to the 
subject in an amount and over a period of time, 
determined to be effective to provide protection against 
neuron loss. 
38. A method of protecting the brain of a subject against 
neuron loss, comprising: 
(a) providing a compound capable of acting through a 
vitamin D receptor; and 
(b) administering the compound to the subject in an 
effective amount and over an effective period of time, 
so as to provide protection against neuron loss. 
39. A method according to claim 38, Wherein the subject 
has an increased risk of neurological impairment by reason 
of at least one of aging and disease. 
10 
16 
40. A method according to claim 39, Wherein the subject 
is suffering from a neurological disease. 
41. A method according to claim 40, Wherein the subject 
is suffering from a neurological disease other than AlZhe 
imer’s disease. 
42. A method for protecting a brain affected With neuron 
loss resulting from a neurodegenerative condition, compris 
ing: 
(a) providing a compound Which protects against neuron 
loss by acting through a vitamin D receptor; and 
(b) administering the compound to the brain in an effec 
tive amount and over an effective period of time, so as 
to provide protection against neuron loss. 
* * * * * 
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